Zoetis (ZTS)
NYSE: ZTS · Veterinary Pharmaceuticals · Parsippany, NJ
Our rating: Positive
Positive reaffirmed at $79.40, high conviction, November 6, 2026.
Breaks if: The Positive call rests on the slowdown being cyclical and the franchise remaining competitively intact. It would be proved wrong if revenue growth turns negative — two consecutive quarters of year-over-year declines reported by mid-2027 — or if free cash flow margin falls below 18% for two straight quarters by that same point. Either outcome would signal structural pressure on the franchise rather than a soft patch, at which point the low multiple becomes a symptom of deterioration, not an opportunity. On the upside, the call would escalate if revenue re-accelerates to 6% or above on a trailing-twelve-month basis within the next four quarters and the FCF-to-net-income gap narrows, confirming the slowdown was transitory.
Key figures
| Market value | $32.1B |
|---|---|
| Revenue, last 12 months | $9.5B |
| Net income, last 12 months | $2.5B |
| Free cash flow, last 12 months | $2.2B |
| Price to earnings | 12.8× |
| Free cash flow yield | 7.0% |
| Dividend yield | 2.7% |
| Operating margin | n/a |
| Return on equity | 57.6% |
| Beta to the S&P 500 | 0.57 |
| Volatility, annualized | 31.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $2.4B | −1.3% | $1.44 | $717M |
| June 30, 2026 | $2.5B | −0.2% | $1.65 | $538M |
| March 31, 2026 | $2.3B | 2.9% | $1.42 | $291M |
| December 31, 2025 | $2.4B | 2.4% | $1.42 | $689M |
| September 30, 2025 | $2.4B | 1.4% | $1.63 | $798M |
| June 30, 2025 | $2.5B | 4.8% | $1.63 | $459M |
| March 31, 2025 | $2.2B | 0.4% | $1.34 | $337M |
| December 31, 2024 | $2.3B | 4.7% | $1.29 | $689M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $2.40B: Claude 38%, Gemini 45%, Mistral 35%
- Diluted earnings per share are at least $1.42: Claude 58%, Gemini 85%, Mistral 75%
- Free cash flow for the quarter is at least $0.69B: Claude 65%, Gemini 80%, Mistral 65%
13 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.